Opterion Health held its first Annual General Meeting at its new headquarters at The 5th Floor, in Muttenz, Baselland.
The hybrid meeting was well attended by our shareholders – in person or online. All agenda items were unanimously approved by all votes represented.
David Ebsworth, Chairman, thanked the two exiting Members of the Board of Directors (BoD), Guido Grentzmann and Andreas Schmidt, for their substantial and valuable contribution over the past years. On behalf of the BoD, he expressed his gratitude to Guido for continuing in his role as Chief Science Officer (CSO), and to Andreas for smoothly handing over his prior task as CFO to Daniel Lustenberger.
Congratulations to the elected members if the Board of Directors: David Ebsworth, Ricardo Cordero and Stefan Wohlfeil.
The entire Opterion team is committed to developing a new solution for peritoneal dialysis that improves the quality of life for patients, their caregivers and loved ones – and increases the survival rate of people who suffer from chronic kidney disease.
Learn more about the approach of Opterion Health: https://opterion.com/